Amgen partners with Biocartis on diagnostic tests for cancer drug
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen lawsuit over cholesterol drug will get new trial
An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →
Ridley-Tree Cancer Center opens with state-of-the-art technology
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ridley-Tree Cancer Center in Santa Barbara celebrates grand opening
The Ridley-Tree Cancer Center celebrated its grand opening on Sept. 13 and its first patients will be treated Sept. 18, ushering in a new era of cancer treatment in Santa Barbara. “It has taken a small village of people over a decade to make this dream a reality,” said Kurt Ransohoff, CEO and chief medical Read More →
FDA approves Amgen cancer treatment biosimilar Mvasi
The U.S. Food and Drug Administration approved a cancer treatment biosimilar developed in partnership between Allergan and Thousand Oaks-based Amgen, the company announced Sept. 13. Mvasi was approved to treat five types of cancer in combination with other therapies. “The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first Read More →
Amgen’s Kyprolis found to increase cancer survival rate
A Phase 3 clinical study of Amgen’s multiple myeloma drug Kyprolis showed that it increased overall survival rate when paired with lenalidomide and dexamethasone versus just those two drugs alone. The drug reduced the risk of death by 21 percent, and patients lived 7.9 months longer when on a regimen that included Kyprolis than those Read More →
FDA gives full approval to Amgen leukemia drug Blincyto
Amgen’s leukemia drug Blincyto received full approval from the U.S. Food and Drug Administration on July 11 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. The biotech giant, headquartered in Thousand Oaks, had previously announced that the drug had been fast-tracked for priority review. The full approval includes data Read More →
